Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Emerging evidence highlights diverse roles of FSTL1 across various malignancies, though its biological significance in bladder carcinogenesis remains unexplored.
Methods: This study systematically interrogated FSTL1 using multidimensional bioinformatics approaches-including tumor microenvironment characterization, survival pattern evaluation, and differential expression profiling-through multiple bladder cancer datasets from TCGA and GEO repositories, with subsequent experimental validation employing in vitro cellular models.
Results: Our findings demonstrate that FSTL1 exhibits significant overexpression in bladder tumors, promotes cancer cell motility through pro-migratory mechanisms, and potentially modulates key components of the tumor microenvironment.
Conclusion: FSTL1 might be a therapeutic target or biomarker for the advancement of bladder cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12094-025-03964-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rhabdomyosarcoma in Pediatric Patients Under 2 Years: Clinical Features and Outcome.
J Pediatr Hematol Oncol
September 2025
Department of Pediatric, The University of Jordan.
Background: Rhabdomyosarcoma (RMS) typically responds well to a combination of treatments with favorable prognosis in children 1 to 9 years old. However, infants may fare worse due to receiving less aggressive local therapy for concerns about long-term effects of surgery/radiation. This study investigates the clinical characteristics, treatment approach, and survival outcomes of RMS in children under 2.
View Article and Find Full Text PDFLong-term complications in patients with bladder-prostate rhabdomyosarcoma treated with brachytherapy: a systematic review.
Pediatr Surg Int
September 2025
Pediatric Surgery Unit, Department of Women's and Children's Health, University of Padua, Via Nicolò Giustiniani, 35100, Padua, Italy.
Introduction: Brachytherapy has been used for the multimodal treatment of pediatric bladder-prostate rhabdomyosarcoma in the last two decades. The aim of this systematic review is to gather the current evidence about this innovative technique with a special focus on long-term outcomes.
Methods: According to PRISMA criteria, PubMed, Scopus, and Web of Science were searched for papers published between 2000 and 2022.
Dosimetry evaluation and uncertainty analysis of Cobalt-60 HDR brachytherapy for cervical cancer in resource-limited settings.
J Cancer Res Clin Oncol
September 2025
Cancer Treatment and Nuclear Cardiology Department, Al Azhar University, Cairo, Egypt.
Background: High-dose-rate (HDR) brachytherapy is essential in the treatment of locally advanced cervical cancer. While Iridium-192 (Ir-192) is commonly used, its short half-life imposes logistical and financial constraints, particularly in low- and middle-income countries (LMICs). Cobalt-60 (Co-60), with a longer half-life and lower operational costs, is a viable alternative.
View Article and Find Full Text PDF